Dr.Reddy’s Laboratories (NYSE:RDY) issued its earnings results on Wednesday. The company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.12, MarketWatch Earnings reports. Dr.Reddy’s Laboratories had a net margin of 11.15% and a return on equity of 19.66%. The business had revenue of $588.00 million during the quarter, compared to analysts’ expectations of $552.28 million.
NYSE RDY opened at $50.57 on Friday. Dr.Reddy’s Laboratories has a 52 week low of $33.33 and a 52 week high of $53.64. The company has a quick ratio of 1.23, a current ratio of 1.81 and a debt-to-equity ratio of 0.01. The business’s fifty day simple moving average is $48.97 and its 200-day simple moving average is $43.07. The firm has a market cap of $8.57 billion, a PE ratio of 30.84 and a beta of 0.48.
A number of equities analysts have weighed in on the stock. Nomura Instinet reiterated a “buy” rating on shares of Dr.Reddy’s Laboratories in a research report on Tuesday, April 21st. TheStreet cut shares of Dr.Reddy’s Laboratories from a “b” rating to a “c” rating in a report on Monday, January 27th. Finally, ValuEngine upgraded shares of Dr.Reddy’s Laboratories from a “sell” rating to a “hold” rating in a report on Friday, March 13th. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $39.50.
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.
Receive News & Ratings for Dr.Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr.Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.